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Abstract: Bcl-2 proteins are critical regulators of mitochondrial membrane permeability and the proapoptotic mitochon-
drial pathway. The family encloses pro- and antiapoptotic factors encoded by over 15 genes, which frequently give rise to 
alternative splice products. Antiapoptotic, proapoptotic multidomain, and proapoptotic BH3-only proteins are character-
ized by the presence of at least one of four Bcl-2 homology domains (BH 1-4). Their expression and activities are con-
trolled by survival pathways as MAP kinases and protein kinase B/Akt, which are in touch with a number of transcription 
factors. In melanoma, the mitochondrial apoptosis pathways and Bcl-2 proteins appear of particular importance for apop-
tosis resistance, which has been addressed in clinical trials applying antisense-Bcl-2. Overexpression or induction of 
proapoptotic Bcl-2 proteins as well as the use of small molecule mimetics for the proapoptotic BH3 domain are further 
promising strategies. 
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INTRODUCTION 
  Cancer is a predominant cause of death worldwide, and 
its importance is even further increasing due to the generally 
extending life expectancy. Currently one in four deaths in the 
United States and in Europe attributes to cancer, and in an 
age range between 45–65, the proportion further increases up 
to 50% [1, 2]. This attributes to the fact that the treatment 
options for disseminated cancer are largely insufficient. 
  A notable example is malignant melanoma of the skin, 
which is characterized by an unbroken high mortality with 
median survival rates of only 8 months in its disseminated 
stage. Patients can be cured only by early and complete sur-
gical excision of the primary tumor, whereas in disseminated 
disease systemic therapies as various chemotherapies, bio-
therapies or vaccination protocols so far were not able to 
improve the dismal prognosis [3-5].  
  Though different mechanisms may contribute to 
chemoresistance, defective apoptosis signaling may be the 
predominant cause in cancer [6, 7]. This corresponds to the 
fact that cancer therapies in general aim at the elimination of 
tumor cells through apoptotic processes. Bcl-2 proteins, 
which will be the topic of this review, are major players in 
the regulation of apoptosis, and melanoma will be used as an 
example for discussing therapeutic strategies for targeting 
Bcl-2 proteins.  
INTRINSIC PATHWAYS TO APOPTOSIS 
  In contrast to necrosis as a kind of accidental cell death, 
apoptosis is an active and physiological process indispensa-
ble for normal tissue homeostasis, which acts as a counter- 
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balance for cell proliferation [8]. Beyond this, it provides 
fundamental safeguard mechanisms in protection from can-
cer by eliminating altered and potentially harmful cells.  
  Different types of cellular damage as well as cellular dys-
regulation such as oncogene activation induce cell-intrinsic 
proapoptotic pathways. Highly active is the mitochondrial 
pathway characterized by a release of mitochondrial 
proapoptotic factors into the cytoplasm [9]. This step is criti-
cally controlled by the family of Bcl-2 proteins (Fig. 1). 
  As a master regulator in apoptosis, the transcription fac-
tor p53 triggers intrinsic pathways. Levels of p53 are kept 
low in healthy cells due to its short half-life and degradation 
by the proteasome pathway. Here the ubiquitin ligase Hdm2 
exerts an important function [10]. In response to DNA dam-
age, hypoxia, oncogene activation or other intrinsic prob-
lems, p53 is stabilized by several possible modification steps 
such as phosphorylation by ATM (ataxia telangiectasia-
mutated), ATR (ATM- and rad3-related) or checkpoint 
kinases (Chk1, Chk2) [11]. As a transcription factor, p53 
drives the expression of various proteins including the cell 
cycle inhibitor p21, which results in a stop of cell division, 
thus providing time for DNA repair. In case of irreparable 
damage however, p53 triggers the transcription of proapop-
totic factors as in particular proapoptotic Bcl-2 proteins such 
as Bax, Noxa, Puma, Bik/Nbk and Bid. Furthermore, cytoso-
lic p53 may also directly interact with Bcl-2 family members 
to trigger mitochondrial apoptosis [12-14]. 
  The family of pro- and antiapoptotic Bcl-2 proteins criti-
cally controls the permeability of organelles as the outer mi-
tochondrial membrane [15]. Once a certain threshold of 
proapoptotic signals is exceeded, a rapid release of mito-
chondrial intermembrane factors is induced. Several factors 
exert characteristic proapoptotic functions when emerging in 
the cytoplasm, as reported for cytochrome C, endonuclease 
G, AIF (apoptosis-inducing factor), Smac/DIABLO (second 410    Current Genomics, 2008, Vol. 9, No. 6  Eberle and Hossini 
mitochondria-derived activator of caspases/direct IAP-
binding protein with low pI) and HtrA2/Omi [16].  
  Cytochrome C triggers the formation of the apoptosome, 
a multiprotein complex enclosing each seven copies of the 
adaptor protein Apaf-1 (apoptosis-activating factor), Cyt C 
and ATP [17]. It allows the binding and activation of initia-
tor caspase-9, which sets up a subsequent caspase cascade 
starting with caspase-3. Caspases (Cysteine-dependent aspar-
tate directed poteases) represent hallmarks in apoptosis. 
They are synthesized as inactive zymogens, and they activate 
each other through cleavage processes thus forming signal 
cascades. Proapoptotic caspases are divided up in initiator 
caspases (2, 8, 9 and 10) and effector caspases (3, 6, and 7) 
[18, 19].  
  Effector caspases themselves have hundreds of different 
cellular protein targets (death substrates), which are inacti-
vated or activated upon cleavage [20]. Thus, CAD (caspase-
activated DNase) in healthy cells is hold in check by binding 
to ICAD (inhibitor of CAD). In course of apoptosis, CAD is 
released by caspase-mediated cleavage of ICAD resulting in 
a cleavage of DNA between nucleosomes visible as a charac-
























Fig. (1). Bcl-2 proteins in the control of the mitochondrial apoptosis pathway. 
Abbreviations: Cyt C, cytochrome C; IAPs, inhibitors of apoptosis proteins; tBid, truncated Bid; BH3-only, BH3-only proteins; AIF, apopto-
sis-inducing factor; EndoG, endonuclease G; Apaf-1, apoptosis-activating factor. Bcl-2 Proteins in Melanoma  Current Genomics, 2008, Vol. 9, No. 6    411 
PARP (poly ADP-ribose polymerase) is inactivated upon 
caspase cleavage ensuring that energy resources are reserved 
for apoptosis as well as that DNA repair does not occur si-
multaneously to DNA fragmentation [22]. The result of such 
changes is the complete reprogramming of the cell for apop-
tosis. 
  The proapoptotic potential of other mitochondrial factors 
is related to the family of inhibitor of apoptosis proteins 
(IAPs). Their function in apoptosis is to block caspase-9 and 
effector caspases, which is achieved by binding to their ac-
tive sites and/or by ubiquitination and targeting caspase deg-
radation. Both Smac/Diablo and HtrA2/Omi have been de-
scribed to augment caspase activation by antagonizing IAP 
proteins [23, 24]. In contrast, the activities of AIF and endo-
nuclease G appear as largely independent from caspase 
pathways. After translocation to the cytosol and to the nu-
cleus, their proapoptotic contribution depends on an endoge-
neous DNAse activity (Endo G) or DNA interaction, chro-
matin condensation and recruitment of downstream nucle-
ases in case of AIF [25]. 
  Thus, the mitochondrial membrane appears as a place for 
integration of different pro- and antiapoptotic signals, where 
the decision about life and death is made. The release of 
proapoptotic proteins appears as the critical step, which de-
pends on the equilibrium between pro- and antiapoptotic 
Bcl-2 proteins. Proapoptotic Bcl-2 proteins support the mito-
chondrial permeability while the antiapoptotic proteins try to 
block it.  
STRUCTURE OF Bcl-2 PROTEINS AND GENOMIC 
ORGANIZATION 
  Bcl-2 proteins are master regulators of the mitochondrial 
pathway. More than twenty known proteins of the family 
(incl. alternative splice products) are categorized according 
to their function (anti or proapoptotic) and according to the 
presence of up to four Bcl-2 homology domains (BH1 – 
BH4). Most antiapoptotic proteins as Bcl-2 or Bcl-xL share 
all four domains, whereas proapoptotic proteins separate into 
and multidomain proteins (Bax, Bak and Bok), which share 
BH 1, 2, 3 BH3-only proteins, which have only BH3(Fig. 2). 
In addition there are other proteins, which do not fit in these 
categories. 
  As concerning the genomic organization of the more than 
15 genes encoding for Bcl-2 proteins, most of them are lo-
cated on different chromosomes. Clustering is seen only oc-
casionally, i.e. Bax and Puma reside in 19q13, and Bcl-2 and 
Noxa are in 18q21 (Table 1). 
MODELS FOR EXPLAINING THE REGULATION OF 
APOPTOSIS BY Bcl-2 PROTEINS 
  Despite intensive research since the identification of Bcl-
2 in 1984 by the t(14;18) translocation in acute B-cell leu-
kaemia [26], the exact mechanism(s), how Bcl-2 proteins 
control mitochondrial permeability, remain partly elusive. 
Different models have been suggested. Accordingly, the 
multidomain proapoptotic proteins are in healthy cells in an 
inactive conformation and either cytosolic (Bax) or only 
loosely attached to mitochondria (Bak). Upon induction of 
apoptosis, they are activated, undergo conformational chan- 
ges and integrate deeper into the outer mitochondrial mem-
brane, to either form channels themselves or trigger opening 
of the permeability transition pore (PTP) [27, 28].  
  In contrast, several antiapoptotic Bcl-2 proteins are per-
manent constituents of the mitochondrial membrane, where 
they protect membrane integrity. They bind to multidomain 
proteins Bax and Bak and thus block their proapoptotic ac-
tivity. Supporting the model, Bcl-2 or Bcl-xL have been 
shown to prevent Bax translocation and activation [29-31], 
and Bcl-xL and Mcl-1 have been shown to sequester Bak in 




















Fig. (2). Bcl-2 family proteins. 
The superfamily of Bcl-2 proteins encloses antiapoptotic factors, 
proapoptotic Bax-like factors and BH3-only proteins. The presense 
of up to four Bcl-2 homology domains (BH 1-4) as well as in some 
proteins the transmembrane domain (TM) is indicated. 
  The BH3-only proteins are regarded as triggers in apop-
tosis control. They are transactivated or post-translationally 
activated by protein modifications in response to diverse 
apoptotic stimuli. Thus, Bid is activated by proteolytic 
cleavage through caspase-8 or granzyme B, Bad is activated 
upon dephosphorylation and Bim is released from cytoskele-
tal structures [33-35]. Upon activation, they bind to the anti-
apoptotic Bcl-2 proteins thus to neutralize their activity and 
leading to a freeing of Bax and Bak [36]. BH3 is required for 
the interaction and binds into a hydrophobic pocket formed 
by BH1, BH2 and BH3 of antiapoptotic Bcl-2 proteins, thus 
leading to their neutralization (Adams and Cory, 2007).  
  Some BH3-only proteins display selective binding to 
specific antiapoptotic Bcl-2 family members as Bad, which 
interacts with Bcl-2, Bcl-w and Bcl-xL but not with Mcl-1, or 
Noxa, which binds to Mcl-1 and Bfl-1 but not Bcl-2 and Bcl-412    Current Genomics, 2008, Vol. 9, No. 6  Eberle and Hossini 
xL. Others as Puma and Bim may be less selective and bind 
to all antiapoptotic Bcl-2 proteins [37]. Thus more than one 
BH3-only protein may be required for induction of apopto-
sis, as demonstrated in HeLa cells, where the release of Bak 
from Bcl-xL and Mcl-1 required activation of Bad and Noxa 
[38]. Antiapoptotic Bcl-2 family members were shown to 
sequester BH3-only proteins at the mitochondria. Thus tBid 
and Bad were found in complex with Bcl-2 and Bcl-xL [39], 
and Bim was found in complex with Mcl-1, which was dis-
rupted upon induction of apoptosis [40, 41].  
  Alternative models suggests that BH3-only proteins may 
also directly interact with Bax and Bak for their activation 
[42], however fluorescence imaging could not demonstrate 
their co-localization [43]. Besides their control of apoptosis 
and besides their localization in mitochondria, Bcl-2 proteins 
are also located in the endoplasmatic reticulum (ER), where 
they are involved in diverse cellular processes, like calcium 
homeostasis, autophagy, the unfolded protein response and 
ER morphogenesis [44].  
ALTERNATIVE SPLICING 
  Some members of the Bcl-2 family are regulated by al-
ternative splicing. A prominent example is Bim, which oc-
curres as a short (BimS), a long (BimL) and an extra long 
protein (BimEL). All three proteins promote apoptosis, but 
have distinct activities and distinct modes of regulation con-
ferred by their interaction with other proteins [45]. Even fur-
ther splice products of Bim have been reported with unde-
termined function. Also for Bax eight splice variants have 
been reported, which have partly different domain structures, 
of which 6 have been shown to exert proapoptotic functions 
[46]. 
  Also several antiapoptotic Bcl-2 proteins are controlled 
by alternative splicing. Thus for Bcl-2, an alternative splice 
product of so far unknown function has been reported (Bcl-
2), which lacks the transmembrane domain and preferen-
tially locates to the cytosol [47]. Also Bfl-1 has a short alter-
native splice variant (Bfl-1S), which localizes to the nucleus 
due to an intrinsic nuclear localization sequence. Also Bfl-1S 
revealed antiapoptotic activities, as determined in co-
expression experiments with Bax [48]. 
  Finally the bcl-x gene is expressed in at least five re-
ported isoforms of different activities. While Bcl-xL (long), 
Bcl-x and Bcl-xES (extra short) are antiapoptotic [49-51], 
Bcl-xS (short) and Bcl-xAK (alternative killer) exert proapop-
totic functions. Most interestingly, Bcl-xAK is the first 
proapoptotic Bcl-2 protein that lacks the BH3 domain [52], 
which so far has been regarded as indispensable for the 
Table 1.  Characteristics of Bcl-2 Proteins 
Proteins Chr.  Location 




Bcl-2 18q21.3  2  Ph 
Bcl-w  14q11.2 - q12  n.r.   
Mcl-1 1q21  2   
Bcl-xL  20pter-p12.1  5  Deph / Ph 
Bfl-1 15q24.3  2   
Proapoptotic 
Bax  19q13.3 - q13.4  8  Deph / Ph / p53 
Bak 6p21.3 n.r.  Con 
Bid  22q11.2  4  Cl / p53  
Bad 11cen-q12.3 n.r.  Deph 
Nbk/Bik  22q13.2-q13.3   n.r.  Ph / p53 
Hrk 12q24.21 n.r.   
Bim 2q12-q13  10  Ph 
Bmf 15q14  n.r.  Ph 
Puma  19q13.3 - q13.4  2  p53 
Noxa 18q21.32  n.r.  p53 
1Chromosomal location of bcl-2 genes. 
2Reported numbers of alternative splice products. For several splice variants, there is no function so far identified, as for several splice variants of Bim and two splice variants of Bax. 
For several proteins the number of splice products has not been reported (n.r.). 
3Mechanisms for activation of Bcl-2 proteins: Ph, phosphorylation; Deph, dephosphorylation; Cl, cleavage; Con, conformational change; p53, transactivation by p53. Bcl-2 Proteins in Melanoma  Current Genomics, 2008, Vol. 9, No. 6    413 
proapoptotic function [36]. Thus even other ways of apopto-
sis regulation by Bcl-2 proteins have to be considered. 
  Alternative splicing of Bcl-2 protein mRNAs seems to be 
regulated by different stimuli, which strongly depended on 
the cell type investigated. Thus for the example of Bcl-x 
proteins, glucocorticoids and progestins may selectively 
trigger bcl-xL mRNA expression and influence the ratio be-
tween bcl-xL and bcl-xS [53]. In glioma cells, Bcl-xL levels 
were increased by TPA, whereas interleukin-6 or GM-CSF 
reduced the proportion of Bcl-xL in leukemia cells [54]. 
  As a selecting factor, the RNA binding protein Sam68 
has been described. Depletion of Sam68 by siRNA caused 
accumulation of antiapoptotic Bcl-xL, whereas Sam68 up-
regulation increased the levels of Bcl-xS [55]. 
Bcl-2 PROTEINS AND MELANOMA APOPTOSIS RE-
SISTANCE 
  The mitochrondrial apoptosis pathways appear of par-
ticular importance for melanoma and are activated in re-
sponse to diverse stimuli also including death ligands [56- 
58]. Antiapoptotic proteins as Bcl-2, Bcl-xL and Mcl-1 are 
highly expressed [59-61], and a high Bcl-2/Bax ratio corre-
lated with apoptosis resistance [62].  
  Regulation of the expression of Bcl-2 has been attributed 
to microphthalmia-associated transcription factor (MITF) 
[63], whereas Bcl-xL expression may depend on NF-B ac-
tivity [64]. Indicative for its critical role, Bcl-2 overexpres-
sion reduced basic apoptosis and sensitivity of melanoma 
cells for proapoptotic stimuli [65, 66]. Despite the well ac-
cepted role of Bcl-2 in melanocyte survival, its contribution 
to chemoresistance of metastasized melanoma remains un-
clear, because high Bcl-2 expression in primary melanomas 
did not correlate with a worsening of prognosis [67], and 
even reduced expression levels were found in metastases, 
where Bcl-xL and Mcl-1 were upregulated [68]. 
  Also expression of proapoptotic family members was 
found in melanoma cells as Bax, Bak, Bid, Bad, PUMA and 
Noxa [69-71], whereas others as Bcl-xS and Bik/Nbk were 
lacking [72, 73]. Proapoptotic Bcl-2 proteins may also be 
upregulated in course of chemotherapy. Thus, taurolidine-
induced apoptosis in melanomas correlated with enhanced 
Bax and reduced Bcl-2 expression [74], and bortezomib in-
duced expression of Noxa [75]. Also a prognostic value of 
proapoptotic Bcl-2 proteins was found, namely down-
regulated Bax and Bak in primary melanomas correlated 
with unfavorable prognosis [76]. 
TRANSCRIPTIONAL REGULATION AND SIGNAL 
CASCADES CONTROLLING Bcl-2 PROTEINS  
  Constitutive activation of central survival pathways as 
mitogen-activated protein kinases (MAPKs), protein kinase 
B (PKB/Akt) and nuclear factor-kappaB (NF-B) character-
istically occur in cancer cells, and substantial evidence con-
nects them with chemoresistance [77]. The canonical MAPK 
pathway is activated downstream of receptor tyrosine 
kinases (RTK) and results in successive phosphorylation of 
Raf, MEK (MAP/extracellular signal-regulated kinase) and 
ERK1/2 (extracellular signal-regulated kinases) [78]. On the 













Fig. (3). Survival pathways involved in regulation of Bcl-2 proteins. 
Four survival pathways (MAPK, PKB-Akt, IKK, JAK/Stat) are indicated which are linked to a number of transcription factors. Some tran-
scription factors are listed here (NF-B, Ets1/2, CREB/ATF family, MITF and FoxO, p53, STAT), which control the expression of Bcl-2 
proteins. 414    Current Genomics, 2008, Vol. 9, No. 6  Eberle and Hossini 
coupled receptors [79]. MAPKs and Akt mediate the phos-
phorylation of multiple apoptosis regulators, and MAPKs in 
addition lead to the activation of many different transcription 
factors. Especially, both Akt and ERK may result in activa-
tion of the NF-B pathway, which triggers the induction of 
antiapoptotic factors such as IAP proteins and Bcl-xL [80].  
  Different cell death signals as well as growth factor dep-
rivation are linked with a regulation of several Bcl-2 pro-
teins. Thus, Bax, Noxa, Puma, Bik/Nbk and Bid are upregu-
lated by p53 [81-83]. Bim can be upregulated by FoxO-3A, 
CEBP (CCAAT-enhancer binding protein-) or CHOP 
(CEBP homologous protein) [84, 85]. In contrast, transcrip-
tional up-regulation of antiapoptotic Bcl-2 proteins often 
depends on survival signals, as Bcl-xL is up-regulated by the 
JAK-STAT pathway [86].  
  Several Bcl-2 proteins are in addition regulated by pro-
tein modification. Thus Mcl-1 is characterized by an only 
short half-life due to its degradation through the proteasome 
pathway, which can be slowed down by phosphorylation 
through ERK [87]. In contrast, Bim is inactivated by ERK 
[88], while Bax and Bad are phosphorylated and inactivated 
by either ERK or Akt [89, 90]. Hereby, either phosphoryla-
tion of Bad, by MAPKs (serine 112) or Akt (serine 136), is 
sufficient for its inhibition [91]. In contrast, phosphorylation 
of Bax by Glycogen synthase kinase-3beta (GSK-3) pro-
motes its activation [92]. Also Bak is activated in response to 
stress-activated protein kinases as MEKK1 and JNK1, but it 
seems not to be phosphorylated itself. Intermediate regula-
tors as possibly BH3-only proteins may be employed [93]. 
  Melanoma is characterized by constitutive ERK1/2 ex-
pression [94, 95], which may result from activating muta-
tions in B-Raf (60%) and N-Ras (30%) [96, 97]. Thus inacti-
vation of Bad and Bim through MAPK phosphorylation as 
well as downregulation of PUMA and upregulation of Mcl-1 
by MAPKs can be assumed as contributing to melanoma cell 
survival and chemoresistance [98-100].  
  The transcription factors activated by MAPKs in melano-
cytic cells enclose MITF, which particularly accounts for 
high Bcl-2 expression [101], as well as factors of the Ets or 
CREB/ATF families, which may be upregulated by MAPKs 
and induce Bcl-2 and/or Bcl-xL [102-104]. Other pro-
survival activities in melanoma cells have been reported for 
ATF-1, ATF-2 and CREB [105, 106].  
  Several antiapoptotic activities of PKB/Akt have been 
identified in melanoma cells, such as Akt-mediated phos-
phorylation of Bad [107] and activation of the NF-B path-
way through an Akt-mediated pathway [108].  
THERAPEUTIC STRATEGIES BASED ON Bcl-2 
PROTEINS AND CONCLUSIONS 
  Because of the critical role of the mitochondrial pathway 
in melanoma, approaches targeting anti- and proapoptotic 
Bcl-2 proteins are of particular interest. This may be achi- 
eved by targeting survival pathways, due to their control 
over the Bcl-2 protein expression. Thus, applying MAPK 
inhibitors induced basic apoptosis and sensitized for pro- 
apoptotic strategies, which correlated to activation of Bad 
and of Bax in vitro as well as in mouse models [109-111]. 
  Proteasome inhibitors were applied to induce apoptosis 
via  inhibition of NF-B. In addition, recent evidence sug-
gested a critical contribution of up-regulation of NOXA 
which appeared early after proteasome inhibition and corre-
lated with apoptosis [112, 113]. As a contrary effect how-
ever, also antiapoptotic Bcl-2 proteins may be upregulated as 
Mcl-1, which is degraded by the proteasome pathway. Thus, 
pro- and antiapoptotic Bcl-2 proteins upregulated by protea-
some inhibitors appear in balance, and better therapeutic 
effects may be obtained with suitable combinations, as re-
cently shown for Mcl-1 siRNA [114, 115].  
  Approaches directly targeting Bcl-2 proteins in mela-
noma appear of particular interest. Thus, Bcl-2 antisense 
oligonucleotide strategies were established. Both in vitro and 
in mouse models, melanoma cells were sensitized for the 
chemotherapeutic dacarbazine [116]. Also, phase I/II clinical 
trials showed positive results [117], and a large phase III trial 
(dacarbazine + Bcl-2 antisense), completed in 2003, showed 
improvements of the clinical response. Significant improve-
ment of the overall survival was found, however, only in a 
subgroup of patients with low serum LDH [118].  
  Complicating an antisense strategy, Bcl-2 expression 
may also be reduced in metastatic melanoma [119], and 
other antiapoptotic Bcl-2 proteins such as Mcl-1 or Bcl-xL 
may substitute for Bcl-2 [120]. Also, antisense strategies 
have been developed for these proteins, which similarly en-
hanced chemosensitivity in vitro and in mouse models [121, 
122]. Due to high expression of several antiapoptotic Bcl-2 
proteins in melanoma, a simultaneous targeting may be 
necessary [119, 123], which may however be difficult to 
realize in the clinic. Other approaches used oligonucleotides 
directed against specific splice sites as the 5'-splice site of 
Bcl-xL, which resulted in reduced ratio of Bcl-xL to Bcl-xS in 
breast cancer cells [124]. 
  As pro- and antiapoptotic Bcl-2 proteins are in balance to 
control the mitochondrial pathway, the overexpression of 
proapoptotic Bcl-2 proteins appears as an alternative strategy 
for the targeting of antiapoptotic factors. The efficacy of 
such strategies has been demonstrated in several in vitro 
studies, where apoptosis was efficiently induced in mela-
noma cells and chemosensitivity was increased by the ex-
ogeneous overexpression of Bcl-xS, Bik/NBK, Bax, Bcl-xAK 
or Noxa [125-128]. 
  Related with such strategies, new developments try to 
mimic the BH3 domain of proapoptotic Bcl-2 proteins, 
which is supposed to bear the main proapoptotic potential 
[129]. These BH3 mimetics are peptides or small molecules 
structurally related to different BH3 domains, and depending 
on their structure, they reveal distinct specificities for block-
ing different antiapoptotic Bcl-2 proteins [130]. 
  Gossypol is a naturally occurring BH3 mimetic isolated 
from cotton seeds, which binds Bcl-xL and Bcl-2. It triggered 
apoptosis even in Bcl-2- or Bcl-xL-overexpressing cells or 
such cells that were deficient for both Bax and Bak, which 
are otherwise resistant to chemotherapy [131, 132]. Also in 
melanoma cell lines, Gossypol efficiently induced cell death 
[133]. Another example that induced apoptosis in melanoma, 
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BH3 domain linked to the HIV TAT protein for better mem-
brane transduction (TAT-Bim) [134].  
  Much work in different tumors has been done with the 
small molecule BH3-mimetic ABT-737, which was identi-
fied by systematic screening [135]. It inhibits Bcl-2, Bcl-xL 
and Bcl-w but appears as inactive against Mcl-1 and A1/Bfl-
1. Several studies demonstrated a sensitization of tumor cells 
for chemotherapy [136-139] or, as shown in melanoma cells, 
it enhanced the proapoptotic effects of co-cultured T-cells 
[140].  
  In particular, resistance to MAPK inhibition based on 
high levels of antiapoptotic Bcl-2 proteins was overcome in 
melanoma cells by another small molecule BH3 mimetic 
(TW-37) developed by computer modeling for binding to 
Mcl-1, Bcl-xL and Bcl-2 [141]. The computer-based design 
of BH3 mimetics may even allow a further improvement of 
their efficacy, particularly the simultaneous targeting of all 
antiapoptotic Bcl-2 proteins is aimed [142].  
  In summary, dysregulation of Bcl-2 proteins appears of 
critical importance for melanoma cell survival and drug re-
sistance, and among the fast increasing number of new tar-
geted therapies, those, which affect Bcl-2 proteins, may es-
pecially apply for melanoma. These are in particular: i) 
blocking of survival pathways to control Bcl-2 protein ex-
pression, ii) antisense strategies against antiapoptotic Bcl-2 
proteins, iii) gene therapy approaches based on overexpres-
sion of proapoptotic Bcl-2 proteins and iv) further develop-
ment of BH3 mimetics. Finally, as a large body of preclinical 
and clinical evidence demonstrates, highly aggressive tumors 
as melanoma may not be defeated by monotherapies, rather 
combinations of several signaling effectors should be envi-
sioned. The challenge of the future will be to identify suit-
able combinations which will also prove efficient in the 
clinic, and strategies targeting Bcl-2 proteins will play a 
dominant role. 
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